1

                            SCHEDULE 14A INFORMATION

          PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

     Filed by the Registrant [ ]
     Filed by a Party other than the Registrant [X]
     Check the appropriate box:
     [ ] Preliminary Proxy Statement  [ ] Confidential, for Use of the
                                          Commission Only (as permitted by Rule
                                          14a-6(e)(2))
     [ ] Definitive Proxy Statement
     [X] Definitive Additional Materials
     [ ] Soliciting Material Pursuant to Section 240.14a-11(c) or Section
         240.14a-12

                          TENET HEALTHCARE CORPORATION
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified in Its Charter)

                      TENET SHAREHOLDER COMMITTEE, L.L.C.
- --------------------------------------------------------------------------------
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
     [X] No fee required.
     [ ] $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6a-6(i)(2) or Item
         22(a)(2) of Schedule 14A.
     [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(l) and
         0-11.

     (1) Title of each class of securities to which transaction applies:

- --------------------------------------------------------------------------------
     (2) Aggregate number of securities to which transaction applies:

- --------------------------------------------------------------------------------
     (3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee
is calculated and state how it was determined):

- --------------------------------------------------------------------------------
     (4) Proposed maximum aggregate value of transaction:

- --------------------------------------------------------------------------------
     (5) Total fee paid:

- --------------------------------------------------------------------------------

     [ ] Fee paid previously with preliminary materials.

     [ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.

     (1) Amount previously paid:

- --------------------------------------------------------------------------------
     (2) Form, Schedule or Registration Statement No.:

- --------------------------------------------------------------------------------
     (3) Filing Party:

- --------------------------------------------------------------------------------
     (4) Date Filed:

- --------------------------------------------------------------------------------
   2
- --------------------------------------------------------------------------------

                    The Tenet Shareholder Committee, L.L.C.

- --------------------------------------------------------------------------------


                                 October 4, 2000


Ms. Linda Selbach
Proxy Manager
Barclays Global Investors, N.A.
45 Fremont Street
San Francisco, CA 94105

Dear Ms. Selbach:

As you consider how to vote your proxy for the election of a portion of the
board of directors at Tenet Healthcare Corporation, the Tenet Shareholder
Committee renews its request that you vote in favor of the Committee's slate.
The Committee's nominees stand for director accountability to shareholders,
sustainable growth, and quality health care.

The critical issues in the election are the prospects for sustainable growth in
shareholder value at Tenet and the current board's callous treatment of
shareholder rights. The September 29, 2000 letter to you from Mr. Silver of
Tenet fails to present a true and complete picture of those issues and falsely
maligns me personally to sway your vote. We would like you to have the truth on
each of these issues.

Financial Performance and Sustainable Growth

The financial performance of Tenet over recent years compares badly to its peer
group and its most comparable competitor, even though the price of the stock has
risen in the last few months. We have already provided extensive materials
describing this poor performance, but the following comparison tells the
story.(1)




                         TENET                                    HCA
                         -----                                    ---
                                        
Stock up 29%                               Stock up 85%

Wrote off $450 million in after-tax        Bought back 96 million shares
"non-recurring" charges.


No incremental value added                 Increased shareholder value another 18%
                                           -- or $3.55 per share -- through spin off
                                           of LifePoint and Triad.


- -------------------
(1) Stock price figures below for Tenet and HCA are based on performance from
September 30, 1998 through September 29, 2000. Other information is from public
financial statements for the two companies for eight quarters, through August
30, 2000 for Tenet and through June 30, 2000 for HCA.


   3

                                                     
Paid $0.01 per share in cash dividends                  Paid $0.16 per share in cash dividends
Total shareholder return of 29%                         Total shareholder return of 104%

Increased A/R days from 67.2 days to 79.8               Reduced A/R days from 46.2 days to
Days                                                    45.0 days

Receivables change USED $394 million in cash            Receivables change ADDED $54 million in
                                                        cash

CEO - former investment banker                          CEO - physician



To lag a competitor by this much is really bad. To lag a competitor that is
preoccupied with defending and settling the largest Medicare fraud case in
history is simply inexcusable.

Corporate Governance

The statements in Mr. Silver's letter about the corporate governance issues,
particularly Tenet's failure to declassify the board and its decision to allow
Mr. Barbakow personally to purchase 2.3 percent of Broadlane, illustrate why
Institutional Shareholder Services ("ISS") concluded that the current board
shows a "brazen indifference toward shareholder" interests.

In his letter, Mr. Silver explains that, in reaching its decision to reject the
twice-expressed desire of shareholders to de-stagger Tenet's board, a committee
of outside Tenet directors carefully studied the issue but nonetheless decided
to keep the classified board. This is no response at all to the overwhelming
desire of the shareholders and is precisely what ISS was criticizing when it
said on September 28, 2000: "This paternalistic argument - that shareholders
somehow must be saved from themselves - does not hold water in today's
investment and corporate governance landscape. Effective corporate governance
depends upon the board being accountable to shareholders ... and we believe the
Tenet board has failed on this account."

Broadlane is indefensible, and Tenet's contorted attempts to explain it only
make the conflicts of interest more apparent. Tenet needs to attract and retain
highly qualified individuals with suitable compensation from Tenet not by
offering Broadlane equity to Tenet employees. Giving Tenet employees such as Mr.
Barbakow a large stake in the financial success of Broadlane when Tenet is
Broadlane's single largest customer creates a direct conflict between the
personal financial interests of Mr. Barbakow and the interests of Tenet, which
Mr. Barbakow is supposed to be safeguarding. To the best of our knowledge Tenet
has not put in place any safeguards to protect against this obvious conflict of
interest. In fact, Tenet's by-laws permit directors to vote on matters in which
they have a personal interest. By contrast, I have sworn to recuse myself from
any matters which pertain to me, should I be elected as a director of Tenet.



                                       2
   4

Finally, since Tenet is also Broadlane's largest shareholder, Tenet management
should benefit the same way as Tenet's shareholders: by owning a stake in Tenet.
If Broadlane is such a good idea, then let it be reflected in the value of
Tenet, where all shareholders benefit.

Mr. Silver's letter claims as a positive corporate governance action the
decision of the Nominating Committee not to re-nominate Mr. Barbakow to serve on
that committee, but that is not what Tenet told ISS. Tenet told ISS that Mr.
Barbakow will serve in an ex-officio (non-voting) capacity, which in our view is
tantamount to membership.

Mr. Silver's letter does not mention the board's "blank check preferred" power.
In our opinion, this is effectively the same thing as a poison pill and serves
no purpose other than to entrench management. He also does not address the
company's incorporation in Nevada.

Personal Slurs

My interests in this proxy contest are the same as yours and the same as every
other shareholder's. When Tenet suggests I am after something for myself, it
ignores what I and my fellow nominees told the Tenet board before this proxy
contest began: "Under no circumstances are we interested in, nor will we accept,
any compensation not offered equally to all other shareholders."

Tenet also told you that I have a history of waging proxy fights, which is only
true if one episode 17 years ago makes a history of waging proxy fights. In that
case, I successfully waged a proxy contest that prevented Southeast Bank from
issuing blank check preferred stock and resulted in a nominee of mine going on
the board.

I also have a record of creating value for shareholders. The stock of both AMI
and OrNda, both of which are now substantial components of Tenet, increased
substantially in value while I was on their respective boards. Unlike other
directors, I have never accepted stock for service as a director. I have always
purchased the stock I have owned, like the other common shareholders of the
companies I have served.

Mr. Silver made other statements designed to lead you to conclude that my
efforts to elect the Committee's slate have a hidden personal motive, but I am
on record with ISS with a pledge, which I confirm to you, that, while on the
board of directors, I will recuse myself from any matter in which I have any
interest. What's more, the facts about the outpatient center across from a Tenet
hospital and about the pending litigation against Tenet contradict any notion
that I am acting out of self-interest.

The facts are that the outpatient facility is operated by a third party. For the
past year, I have had no ownership interest in the entity operating the
outpatient facility. I do have longstanding ownership interests in real property
near a Tenet hospital, and the litigation



                                       3
   5

relates to these interests and a cross-parking agreement (necessitated because
Tenet's predecessor chose not to buy the adjoining properties despite an offer
to sell them) that Tenet now seeks to breach. To avoid any possible perception
that my concerns about the poor performance of Tenet's board was related to this
litigation, I placed these real property interests in an irrevocable trust with
an independent trustee and so notified Tenet before beginning this proxy fight.

Tenet shareholders need directors that are accountable and committed to
sustainable value for all shareholders. That is what we would bring to the Tenet
board. Please vote for the Committee's slate by returning a striped GOLD proxy
card with your vote in favor of the Committee's slate.


                                          Very truly yours,



                                          M. Lee Pearce, M.D.
                                          Chairman
                                          The Tenet Shareholder Committee



                                       4